09.09.2026
Therapeutics
$2,042,983.00
36 months
Autologous M(IL4) transfers for Crohn's disease: product development, safety testing and first-in-human trial
To determine the safety, stability and effectiveness of a modified macrophage product in pre-clinical models followed by regulatory body-approved first-in-human safety testing